I
Ira Pastan
Researcher at Laboratory of Molecular Biology
Publications - 1304
Citations - 113191
Ira Pastan is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 160, co-authored 1286 publications receiving 110069 citations. Previous affiliations of Ira Pastan include Heidelberg University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins
TL;DR: The results suggest that anti-FCRL1 immunotoxin E9(Fv)-PE38 exhibits remarkably specific cytotoxicity and merits further evaluation for the treatment of FCRL1-positive malignancies, including CLL, HCL, FL, MCL, and other B-NHL.
Journal ArticleDOI
Decrease in the levels of nuclear RNA precursors for alpha 2 collagen in Rous sarcoma virus transformed fibroblasts.
Enrico V. Avvedimento,Yoshihiko Yamada,Elizabeth Lovelace,Gabriel Vogeli,Benoit de Crombrugghe,Ira Pastan +5 more
TL;DR: The results indicate that the levels of the primary transcript of alpha 2 collagen RNA are much lower in RSV-CEF than in CEF, and suggest, but do not prove, that the effect of the transforming protein p60src on the synthesis ofalpha 2 collagen is mediated by a transcriptional control mechanism.
Epidermal growth factor (EGF) receptor gene transcription
TL;DR: Fractionation showed that a DEAE-Sepharose fraction (BA) contained a novel factor, which specifically stimulated EGF receptor transcription 5- to 10-fold, which may activate transcription of the proto-oncogene through a weak or indirect interaction with the DNA template.
Journal ArticleDOI
Identification of a transformation-specific protein induced by a rous sarcoma virus
TL;DR: Pulsechase experiments indicate that this 56,000 dalton molecular weight protein is extremely unstable, with a half-life of about 20 min, and does not serve as a precursor to any of the detectable virion polypeptides.
Journal ArticleDOI
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Robert J. Kreitman,Claire Dearden,Pier Luigi Zinzani,Julio Delgado,Tadeusz Robak,Philipp le Coutre,Bjørn Tore Gjertsen,Xavier Troussard,Gail J. Roboz,Lionel Karlin,Douglas E. Gladstone,Nataliya Kuptsova-Clarkson,Shiyao Liu,Priti Patel,Federico Rotolo,Emmanuel Mitry,Ira Pastan,Francis J. Giles +17 more
TL;DR: Moxetumomab pasudotox as mentioned in this paper is a recombinant CD22-targeting immunotoxin that is used to treat relapsed/refractory (R/R) hairy cell leukemia (HCL).